HUMAN-POWERED DRUG DISCOVERY

HC WAINWRIGHT GLOBAL INVESTMENT CONFERENCE
MAY 23-26, 2022
SAFE HARBOR

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.'s (formerly Cancer Genetics, Inc.) expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future strategic collaborations and transactions in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, achieve profitability and increase sales of our pre-clinical services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger with StemoniX, Inc., and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2020, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio, Inc. disclaims any obligation to update these forward-looking statements.
Underperformance of Widely Used Models for Predicting Drug Efficacy and Safety

Late Introduction of Human Biology in the R&D Process Leads to High Failure and Cost

**Deep Expertise and Global Presence in Drug Discovery**

Human Biology and Data Science Driven Proprietary Discovery Engine

Focused on Efficiently Discovering Novel Therapeutics for Neurological Diseases

Nasdaq: VYNT
A “human first” strategy using patient-derived iPSC organoids for screening
- **accelerate drug discovery** by reducing failure rates
- **drive clinical translation** of drug candidates
- **improve clinical success** by picking appropriate genetically defined patient populations

Focused on models for **CNS genetic disorders**
- established the first models for the monogenetic disorders **RETT syndrome** and **CDKL5**
- development of models for known **familial Parkinson’s disease** genes
  potential to expand into the more common sporadic/idiosyncratic populations for **Parkinson’s disease**
FIRST QUARTER 2022 HIGHLIGHTS

- Collaboration with OrganoTherapeutics
- Insightful data readouts on disease phenotype in Rett Syndrome and CDKL5
- Entering into two financing vehicles & increased corporate visibility
- Completing lab facility consolidation & Ongoing sale process for preclinical CRO business
**Our Therapeutic Assets**

<table>
<thead>
<tr>
<th>PROGRAM</th>
<th>INDICATION</th>
<th>PRECLINICAL</th>
<th>CLINICAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>VYNT-0126</td>
<td>Rett Syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORAI-xxxx *</td>
<td>Rett Syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VYNT-xxxx *</td>
<td>CDKL5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VYNT-xxxx</td>
<td>Parkinson’s Disease</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* We are in partnerships for the use of artificial intelligence systems with Atomwise for the discovery of a novel Rett Syndrome compound and Cyclica for the discovery of a novel CDKL5 compound.
R&D Team

Robert Fremeau, PhD
Chief Science Officer

20+ years drug discovery experience in industry and academia with multiple novel candidates across neuro disease indications
Expertise in small molecule hit-to-lead and lead optimization
Ph.D. Biochemistry | Neurobiology & Cancer

Cassiano Carromeu, PhD
Rett Core Team Lead

Inventor of the microBrain® platform for drug screening for StemoniX
28+ Papers, 3 Book Chapters, 3 Patents
Pioneer in modeling neurodevelopmental disorders using iPSCs based spheroids and organoids
Ph.D. Biotechnology | Stem Cell Neurobiologist

Andrew LaCroix, PhD
Sr. Scientist

Expert in cellular and molecular bioengineering
Lead high throughput screening scientist
Ph.D. Biomedical Engineer | Data Scientist

Jorge Urresti, PhD
Sr. Scientist

10+ years in molecular biology research in new stem cell models
Experience in cell culture, CRISPR, and Data science and well-published in impact journals
Ph.D. Molecular Biologist | Stem Cell Neurobiologist

Nasdaq: VYNT
Rett Syndrome

- Neurological disorder occurring almost exclusively in females
- Typically presents at between 6 to 18 months
- Patients experience a period of rapid clinical decline that stabilizes later in life
- Occurs worldwide, impacting all racial and ethnic groups

Genetics

- Caused by mutations of the MECP2 gene located on the X chromosome
- >200 different mutations found on the MECP2 gene

Source: International Rett Syndrome Foundation
Rett Syndrome

Affects 1 in 10,000 females
Currently 20,000 in US & 50,000 globally

$1.5B Total Market Opportunity

11 Active Clinical Trials
0 APPROVED THERAPEUTICS FOR TREATMENT

Source: International Rett Syndrome Foundation
CDKL5 Deficiency Disorder

- Severe neurodevelopmental brain disease
- Characterized by early-onset epilepsy and intellectual and motor impairments
- Genetic testing available to determine if patients have mutation in CDKL5 gene
- Limited knowledge of pathology has hindered development of therapeutics

Genetics

- X-linked disease caused by mutations in CDKL5 gene
- Mutations can cause deficiencies in kinase that regulates neuronal morphology through cytoplasmic signaling and gene expression

Source: Tao et al., 2004
CDKL5 Deficiency Disorder

Affects 1 in 50,000 (mostly) female patients
Approximately 75 to 100 newborns per year
Currently 12,500 patients in US and EU

BY THE NUMBERS

Awards

- 43 Early Clinical Trials
- 1 Approved Therapeutics for Treatment

* Still being determined

Total Market Opportunity

< $1B*

Nasdaq: VYNT
Parkinson’s Disease

- Caused by a loss of nerve cells in substantia nigra of the brain that make dopamine

- Decrease in dopamine levels cause abnormal brain activity, leading to impaired movement and muscle stiffness

- Cannot be cured, but medications can help control symptoms.

- In some later cases, surgery may be advised.

https://www.fortunebusinessinsights.com/industry-reports/parkinsons-disease-drugs-market-100655
Parkinson’s Disease

Affects about 10 million patients
Approximately 60,000 diagnosed per year in US

Total Market Opportunity $5.3B

BY THE NUMBERS

142 Active Clinical Trials

37 APPROVED THERAPEUTICS FOR TREATMENT

Nasdaq: VYNT
Human microOrgan™ Discovery Platform
Paradigm for high-throughput clinic-based screening

Drive Successful Clinical Outcomes Through Patient-Based Discovery

Patient-derived iPSC Organoids
Establish translatable bio-markers to drive Discovery and de-risked clinical trials

Biomarker-based Screening
Identify, validate, and de-risk targets and hits across multiple biological endpoints

Discovery
Targets & Hits Novel & Repurposed

Value Creation
Rapidly discover and advance first and/or best in class targets and molecules

Utilize patient biology, high-throughput screening and data science to drive de-risked target and hit discovery
Case Study: Discovery with Patient-derived Models and Data Science

Rett Syndrome

Our data science analysis can quantify impact of treatments across measures of biology and rank them in order of efficacy and safety.

<table>
<thead>
<tr>
<th>Target</th>
<th>Cmpd</th>
<th>Functional Rescue</th>
<th>Functional Toxicity</th>
<th>Structural Toxicity</th>
<th>Viability (ATP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>✓</td>
<td>(100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>✓</td>
<td>(92%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>✓</td>
<td>(86%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>✓</td>
<td>(83%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>X</td>
<td>(64%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>X</td>
<td>(68%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>X</td>
<td>(67%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>X</td>
<td>(61%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>X</td>
<td>(66%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>X</td>
<td>(67%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>✓</td>
<td>(89%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>✓</td>
<td>(81%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>X</td>
<td>(67%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>X</td>
<td>(68%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>✓</td>
<td>(81%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>X</td>
<td>(63%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>✓</td>
<td>(72%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>X</td>
<td>(68%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>X</td>
<td>(63%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>X</td>
<td>(64%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>X</td>
<td>(69%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>X</td>
<td>(47%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>X</td>
<td>(50%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Our patient derived stem cell models provide representative disease modeling and allow for drug toxicity studies.

Rapid Qualitative Analysis

Visualization & Multivariable Validation
Underperformance of Widely Used Models for Predicting Drug Efficacy and Safety

Late Introduction of Human Biology in the R&D Process Leads to High Failure and Cost

Deep Expertise and Global Presence in Drug Discovery

Human Biology and Data Science Driven Proprietary Discovery Engine

Focused on Efficiently Discovering Novel Therapeutics for Neurological Diseases
Leveraging Human Biology and Data Science to Discover New Therapies for Neurological Diseases